HELP · Why this verdict
Why Helus Pharma (HELP) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Helus Pharma is a pre-revenue biotechnology company with quality at 1.2/10, negative free cash flow and 254% implied volatility, so any upside to the $12.48 technical resistance (39.3%) comes with high binary and funding risk ahead of earnings in 4 days.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company is cash-burning with negative free cash flow, no competitive moat and a weak Piotroski F-Score of 2/9, putting quality at 1.2/10, below the 4.0 minimum. Quality breakdown | Piotroski F-Score improves above 4 and quality rises above 4.0 as cash burn narrows. | →Stable |
| CounterClinical-stage biotechs are expected to burn cash, and the current ratio component of 5 shows some liquidity runway. | ||
Reported quarterly revenue was $0.0M in each of the last five quarters, so the business has no commercial revenue base yet. Revenue quarters | The company reports its first quarterly revenue above $1M within 12 months. | ↓Deteriorating |
| CounterFor a binary-outcome biotech, value depends on trial results and not revenue, so zero revenue is normal and says little about pipeline value. | ||
Helus missed EPS in 3 of the last 4 quarters, with misses of -5.8%, -39.8% and -24.5%, and one 8.4% beat in August 2026; the next report is due 2026-11-12. Earnings | EPS surprise stays positive at the 2026-11-12 report. | ↓Deteriorating |
| CounterMisses were mostly small in absolute terms and the most recent report was a beat, suggesting estimates are catching up. | ||
The $12.48 resistance is 39.3% above the $8.96 price against 7.0% downside to the $8.33 stop, after an uptrend pullback (RSI 34); the raw analyst target of $41.03 was rejected as implausible, so this is a technical target only. Targets | Price rises toward $12.48 while holding above the $8.33 stop level. | →Stable |
| CounterMomentum is 3.1/10 with falling on-balance volume, and with no reliable analyst target the upside rests on chart levels alone. | ||
Implied volatility of 254%, a drawdown of 41% from the 52-week high and a binary biotechnology profile make large moves in either direction likely around earnings. Risk breakdown | Implied volatility falls below 150% once clinical and financial uncertainty clears. | ↑Improving |
| CounterExtreme volatility means the upside can be large if trials succeed, and a bullish insider buy and institutional accumulation are modest positives. | ||
The company is cash-burning with negative free cash flow, no competitive moat and a weak Piotroski F-Score of 2/9, putting quality at 1.2/10, below the 4.0 minimum.
→StableQuality breakdown
- Expectation
- Piotroski F-Score improves above 4 and quality rises above 4.0 as cash burn narrows.
CounterClinical-stage biotechs are expected to burn cash, and the current ratio component of 5 shows some liquidity runway.
Reported quarterly revenue was $0.0M in each of the last five quarters, so the business has no commercial revenue base yet.
↓DeterioratingRevenue quarters
- Expectation
- The company reports its first quarterly revenue above $1M within 12 months.
CounterFor a binary-outcome biotech, value depends on trial results and not revenue, so zero revenue is normal and says little about pipeline value.
Helus missed EPS in 3 of the last 4 quarters, with misses of -5.8%, -39.8% and -24.5%, and one 8.4% beat in August 2026; the next report is due 2026-11-12.
↓DeterioratingEarnings
- Expectation
- EPS surprise stays positive at the 2026-11-12 report.
CounterMisses were mostly small in absolute terms and the most recent report was a beat, suggesting estimates are catching up.
The $12.48 resistance is 39.3% above the $8.96 price against 7.0% downside to the $8.33 stop, after an uptrend pullback (RSI 34); the raw analyst target of $41.03 was rejected as implausible, so this is a technical target only.
→StableTargets
- Expectation
- Price rises toward $12.48 while holding above the $8.33 stop level.
CounterMomentum is 3.1/10 with falling on-balance volume, and with no reliable analyst target the upside rests on chart levels alone.
Implied volatility of 254%, a drawdown of 41% from the 52-week high and a binary biotechnology profile make large moves in either direction likely around earnings.
↑ImprovingRisk breakdown
- Expectation
- Implied volatility falls below 150% once clinical and financial uncertainty clears.
CounterExtreme volatility means the upside can be large if trials succeed, and a bullish insider buy and institutional accumulation are modest positives.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.8 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 7.9 |
| MACD | 2.0 |
| OBV | 6.6 |
| MA position | 4.0 |
| Volume | 3.5 |
- ▸Uptrend pullback (RSI 36) - buy opportunity
- ▸Above 200-day MA
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 339%
Insider
7.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider buying (low materiality) — $38,730 (0.006% of mkt cap)
- ▸Institutions accumulating
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.3 |
| growth rank | 5.0 |
Technical
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.1 |
| support resistance | 6.7 |
| 52w position | 2.4 |
| gap | 4.0 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| days to cover | 9.2 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 9.3 |
- ▸High IV: 234%
- ▸Above max pain $2
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/3M
- ▸Earnings in 3 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:4.8>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:3d<=7d
Warning (2)
- MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+22.8%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 3d<=7d outcome against Insider at 7.5 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 7.5, Sentiment at 6.6, and Risk (lower is worse) at 5.2; the weakest are Quality at 1.2, Catalyst at 2.5, and Peer rank at 3.8. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burning Weak Fundamentals
Trip ifPiotroski F-Score rises above 4 from the current 2.
- P2Pre Revenue Status
Trip ifQuarterly revenue exceeds $1M from the current $0.
- P3Earnings Miss Pattern
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P4Technical Upside To Resistance
Trip ifShare price falls below the $8.33 stop level, about 7% below $8.96.
- P5Extreme Volatility Binary Risk
Trip ifImplied volatility falls below 150% from the current 254%.